{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:05:45Z","timestamp":1761897945354,"version":"build-2065373602"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,5]],"date-time":"2023-12-05T00:00:00Z","timestamp":1701734400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81974007","82270214"],"award-info":[{"award-number":["81974007","82270214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFC1316204"],"award-info":[{"award-number":["2019YFC1316204"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.intimp.2023.111277","type":"journal-article","created":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T15:26:26Z","timestamp":1701876386000},"page":"111277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Development of a nomogram prognostic model for early Grade\u00a0\u2265\u00a03 infection in newly diagnosed multiple myeloma based on immunoparesis"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-0083-2906","authenticated-orcid":false,"given":"Min","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianwen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aoshuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8053-025X","authenticated-orcid":false,"given":"Chunyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.111277_b0005","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 2021, 71(1): p. 7-33.","DOI":"10.3322\/caac.21654"},{"issue":"8","key":"10.1016\/j.intimp.2023.111277_b0010","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1007\/s002770100330","article-title":"Risk factors for early death in patients undergoing treatment for multiple myeloma","volume":"80","author":"Murakami","year":"2001","journal-title":"Ann. Hematol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111277_b0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.intimp.2023.111277_b0020","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1086\/605664","article-title":"Infections in patients with multiple myeloma in the era of high-dose therapy and novel agents","volume":"49","author":"Nucci","year":"2009","journal-title":"Clin. Infect. Dis."},{"issue":"36","key":"10.1016\/j.intimp.2023.111277_b0025","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.intimp.2023.111277_b0030","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1054\/bjoc.1999.1088","article-title":"Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma","volume":"82","author":"Robertson","year":"2000","journal-title":"Br. J. Cancer"},{"issue":"6","key":"10.1016\/j.intimp.2023.111277_b0035","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9343(95)00043-7","article-title":"Prophylactic antibiotics for the prevention of early infection in multiple myeloma","volume":"100","author":"Oken","year":"1996","journal-title":"Am. J. Med."},{"issue":"12","key":"10.1016\/j.intimp.2023.111277_b0040","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"University of Rochester Cancer Center and the Eastern Cooperative Oncology Group. Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.intimp.2023.111277_b0045","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s12185-014-1672-1","article-title":"Effect of levofloxacin prophylaxis for prevention of severe infections in multiple myeloma patients receiving bortezomib-containing regimens","volume":"100","author":"Jung","year":"2014","journal-title":"Int. J. Hematol."},{"issue":"2","key":"10.1016\/j.intimp.2023.111277_b0050","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/0090-1229(80)90097-5","article-title":"Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis","volume":"17","author":"Pruzanski","year":"1980","journal-title":"Clin. Immunol. Immunopathol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111277_b0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin. Proc."},{"issue":"9","key":"10.1016\/j.intimp.2023.111277_b0060","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1001\/jamaoncol.2019.1568","article-title":"Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma","volume":"5","author":"Landgren","year":"2019","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.intimp.2023.111277_b0065","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2013-12-539940","article-title":"Determining the significance of MGUS","volume":"123","author":"Merlini","year":"2014","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.intimp.2023.111277_b0070","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.intimp.2023.111277_b0075","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bjh.18182","article-title":"Recovery of polyclonal immunoglobulins during treatment in patients ineligible for autologous stem-cell transplantation is a prognostic marker of longer progression-free survival and overall survival","volume":"198","author":"D\u00e1vila","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.intimp.2023.111277_b0080","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/bjh.16488","article-title":"Characterisation and prognostic impact of immunoparesis in relapsed multiple myeloma","volume":"189","author":"Chakraborty","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.intimp.2023.111277_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14092278","article-title":"Clinical Considerations for Immunoparesis in Multiple Myeloma","volume":"14","author":"Chahin","year":"2022","journal-title":"Cancers (basel)"},{"issue":"3","key":"10.1016\/j.intimp.2023.111277_b0090","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/jcp.48.3.260","article-title":"Immunological factors and risk of infection in plateau phase myeloma","volume":"48","author":"Hargreaves","year":"1995","journal-title":"J. Clin. Pathol."},{"issue":"5","key":"10.1016\/j.intimp.2023.111277_b0095","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2007.06705.x","article-title":"Immunodeficiency and immunotherapy in multiple myeloma","volume":"138","author":"Pratt","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.intimp.2023.111277_b0100","article-title":"HLC Pair Suppression as a Risk Factor for Bacterial Bloodstream Infections and Early Mortality in Newly Diagnosed Intact Immunoglobulin Multiple Myeloma Patients","volume":"11","author":"de Veas","year":"2021","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.intimp.2023.111277_b0105","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ejh.13190","article-title":"Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study","volume":"102","author":"S\u00f8rrig","year":"2019","journal-title":"Eur. J. Haematol."},{"issue":"1","key":"10.1016\/j.intimp.2023.111277_b0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ejh.13066","article-title":"Risk factors for blood stream infections in multiple myeloma: A population-based study of 1154 patients in Denmark","volume":"101","author":"S\u00f8rrig","year":"2018","journal-title":"Eur. J. Haematol."},{"issue":"12","key":"10.1016\/j.intimp.2023.111277_b0115","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.intimp.2023.111277_b0120","first-page":"1022","article-title":"Risk factors for the development of bacterial infections in multiple myeloma treated with two different vincristine-adriamycin-dexamethasone schedules","volume":"88","author":"Cesana","year":"2003","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.intimp.2023.111277_b0125","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12879-016-2155-1","article-title":"Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma","volume":"17","author":"Huang","year":"2017","journal-title":"BMC Infect. Dis."},{"issue":"2","key":"10.1016\/j.intimp.2023.111277_b0130","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/10428194.2015.1088647","article-title":"Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?","volume":"57","author":"de la Rubia","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.intimp.2023.111277_b0135","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/413149","article-title":"The impact of hyperglycemia on risk of severe infections during early period of induction therapy in patients with newly diagnosed multiple myeloma","volume":"2014","author":"Jung","year":"2014","journal-title":"Biomed. Res. Int."},{"issue":"50","key":"10.1016\/j.intimp.2023.111277_b0140","doi-asserted-by":"crossref","first-page":"e2305","DOI":"10.1097\/MD.0000000000002305","article-title":"Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma","volume":"94","author":"Hsu","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.intimp.2023.111277_b0145","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2023.111277_b0150","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.772015","article-title":"Development of a Risk Assessment Model for Early Grade \u2265 3 Infection During the First 3 Months in Patients Newly Diagnosed With Multiple Myeloma Based on a Multicenter Real-World Analysis in China","volume":"12","author":"Shang","year":"2022","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.intimp.2023.111277_b0155","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade \u2265 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.intimp.2023.111277_b0160","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J."},{"issue":"10","key":"10.1016\/j.intimp.2023.111277_b0165","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2014.110","article-title":"Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.intimp.2023.111277_b0170","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/leu.2010.60","article-title":"Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management","volume":"24","author":"Kyle","year":"2010","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.intimp.2023.111277_b0175","doi-asserted-by":"crossref","first-page":"e0188988","DOI":"10.1371\/journal.pone.0188988","article-title":"Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population","volume":"12","author":"S\u00f8rrig","year":"2017","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.intimp.2023.111277_b0180","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2023.111277_b0185","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S1470-2045(19)30649-7","article-title":"Reducing infection-related morbidity and mortality in patients with myeloma","volume":"20","author":"Ramasamy","year":"2019","journal-title":"Lancet Oncol."},{"issue":"12","key":"10.1016\/j.intimp.2023.111277_b0190","doi-asserted-by":"crossref","first-page":"603","DOI":"10.5694\/j.1326-5377.1980.tb135163.x","article-title":"Septicaemia in patients with haematological malignant disease","volume":"1","author":"King","year":"1980","journal-title":"Med. J. Aust."},{"issue":"6","key":"10.1016\/j.intimp.2023.111277_b0195","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/00007611-197906000-00032","article-title":"Hemophilus influenzae septicemia and polyarthritis in multiple myeloma","volume":"72","author":"Saba","year":"1979","journal-title":"South Med. J."},{"key":"10.1016\/j.intimp.2023.111277_b0200","doi-asserted-by":"crossref","first-page":"9947","DOI":"10.2147\/OTT.S222813","article-title":"Fibrinogen Is A Coagulation Marker Associated With The Prognosis Of Endometrial Cancer","volume":"12","author":"Li","year":"2019","journal-title":"Onco. Targets Ther."},{"issue":"9","key":"10.1016\/j.intimp.2023.111277_b0205","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/jcp.2010.076349","article-title":"Elevated D-dimers are also a marker of underlying malignancy and increased mortality in the absence of venous thromboembolism","volume":"63","author":"Knowlson","year":"2010","journal-title":"J. Clin. Pathol."},{"issue":"8","key":"10.1016\/j.intimp.2023.111277_b0210","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3324\/haematol.2011.054718","article-title":"High D-dimer levels are associated with poor prognosis in cancer patients","volume":"97","author":"Ay","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.intimp.2023.111277_b0215","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2018.01.037","article-title":"Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review","volume":"163","author":"Samuelson Bannow","year":"2018","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.intimp.2023.111277_b0220","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.thromres.2015.09.021","article-title":"Clinical outcomes of venous thromboembolism with dalteparin therapy in multiple myeloma patients","volume":"136","author":"Lee","year":"2015","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.intimp.2023.111277_b0225","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/bjh.13176","article-title":"Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10","volume":"168","author":"Kovacs","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.intimp.2023.111277_b0230","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1515\/cclm-2020-0188","article-title":"Prominent changes in blood coagulation of patients with SARS-CoV-2 infection","volume":"58","author":"Han","year":"2020","journal-title":"Clin. Chem. Lab. Med."},{"issue":"10","key":"10.1016\/j.intimp.2023.111277_b0235","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejim.2015.10.024","article-title":"D-dimer and histamine in early stage bacteremia: A prospective controlled cohort study","volume":"26","author":"Schwameis","year":"2015","journal-title":"Eur. J. Intern. Med."},{"issue":"1","key":"10.1016\/j.intimp.2023.111277_b0240","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1186\/s12879-020-05412-w","article-title":"Assessment of infection in newly diagnosed multiple myeloma patients: risk factors and main characteristics","volume":"20","author":"Lin","year":"2020","journal-title":"BMC Infect. Dis."},{"issue":"5","key":"10.1016\/j.intimp.2023.111277_b0245","first-page":"4049","article-title":"Long-acting granulocyte colony-stimulating factor in primary prophylaxis of early infection in patients with newly diagnosed multiple myeloma","volume":"30","author":"Ding","year":"2022","journal-title":"Support Care Cancer"},{"issue":"12","key":"10.1016\/j.intimp.2023.111277_b0250","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.21037\/tcr-21-1627","article-title":"Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma","volume":"10","author":"Huang","year":"2021","journal-title":"Transl. Cancer Res."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923016041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923016041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:16:12Z","timestamp":1761588972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923016041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":50,"alternative-id":["S1567576923016041"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111277","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a nomogram prognostic model for early Grade\u00a0\u2265\u00a03 infection in newly diagnosed multiple myeloma based on immunoparesis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111277"}}